rapid
identif
highli
specif
potent
drug
candid
continu
substanti
challeng
tradit
pharmaceut
approach
moreov
mani
target
proven
intract
tradit
smallmolecul
protein
approach
therapeut
base
rna
interfer
rnai
offer
power
method
rapidli
identifi
specif
potent
inhibitor
diseas
target
molecular
class
numer
proofofconcept
studi
anim
model
human
diseas
demonstr
broad
potenti
applic
rnai
therapeut
major
challeng
success
drug
develop
identifi
deliveri
strategi
translat
clinic
advanc
area
commenc
multipl
clinic
trial
rnai
therapeut
candid
transform
modern
medicin
may
soon
realiz
rnase
dicer
initi
rnai
cleav
doublestrand
rna
substrat
small
fragment
nucleotid
length
fig
sirna
duplex
incorpor
protein
complex
call
rnainduc
silenc
complex
risc
fig
biochem
analysi
identifi
argonaut
protein
risc
respons
mrna
cleavag
crystal
structur
rnabound
report
reveal
key
interact
risc
activ
sens
nonguid
strand
sirna
duplex
cleav
manner
cleav
mrna
substrat
prevent
sensestrand
cleavag
chemic
modif
reduc
sirna
potenc
vitro
howev
experiment
context
import
sirna
highli
stabil
uncleav
sens
strand
highli
activ
smallmolecul
pharmaceut
drug
almost
without
except
meet
lipinski
rule
criteria
includ
high
lipophil
molecular
weight
sharp
contrast
sirna
natur
lack
druglik
properti
owe
larg
size
two
turn
nucleic
acid
doubl
helix
nearli
anion
charg
due
phosphodiest
backbon
high
molecular
weight
kda
aqueou
solut
sugarphosph
backbon
expos
water
sirna
extrem
hydrophil
heavili
hydrat
furthermor
sirna
unstabl
serum
result
degrad
serum
nucleas
contribut
short
halfliv
vivo
although
molecular
weight
sirna
reduc
molecul
made
druglik
judici
use
chemic
modif
sugar
backbon
base
oligoribonucleotid
chemic
modifi
sirna
duplex
evalu
cellbas
assay
anim
model
modif
discuss
rnai
fundament
cellular
mechan
silenc
gene
express
har
develop
new
drug
reduct
express
patholog
protein
rnai
applic
class
molecular
target
includ
difficult
modul
select
tradit
pharmaceut
approach
involv
small
molecul
protein
consequ
rnai
therapeut
drug
class
potenti
exert
transform
effect
modern
medicin
rnai
target
mrna
enzymat
cleav
lead
decreas
abund
correspond
protein
specif
key
featur
mechan
synthet
small
interf
rna
sirna
leverag
natur
occur
rnai
process
manner
consist
predict
regard
extent
durat
action
addit
viral
deliveri
short
hairpin
rna
shrna
repres
altern
strategi
har
rnai
nonvir
deliveri
sirna
viral
deliveri
shrna
advanc
potenti
rnaibas
therapeut
approach
review
provid
overview
molecular
mechan
rnai
silico
design
sirna
shrna
specif
target
interest
context
current
concept
relat
chemic
structur
specif
potenc
use
chemic
modif
confer
stabil
exoand
endonucleas
present
biolog
fluid
tissu
strategi
facilit
cellular
deliveri
vivo
conjug
complex
lipidbas
approach
facilit
cellular
uptak
summar
numer
public
date
demonstr
robust
efficaci
rnai
anim
model
human
diseas
upon
direct
local
well
system
administr
proofofconcept
studi
support
rnai
basi
new
therapeut
approach
potenti
chang
treatment
human
diseas
importantli
discuss
clinic
trial
recent
commenc
rnai
therapeut
candid
studi
treatment
agerel
macular
degener
amd
respiratori
syncyti
viru
rsv
infect
shown
figur
stabil
nucleas
degrad
achiev
introduc
phosphorothio
ps
backbon
linkag
end
exonucleas
resist
modif
relat
endonucleas
resist
sirna
motif
consist
entir
nucleotid
enhanc
plasma
stabil
increas
vitro
potenc
one
site
motif
show
improv
potenc
unmodifi
sirna
use
phosphatas
tensin
homolog
pten
target
effect
sugar
modif
guid
nonguid
strand
evalu
hela
cell
activ
depend
posit
modif
guidestrand
sequenc
sirna
modifi
residu
end
guid
strand
seem
less
activ
modifi
end
sugar
gener
well
toler
guid
strand
wherea
modif
result
loss
activ
regardless
placement
posit
construct
incorpor
nonguid
strand
sirna
notabl
effect
activ
sugar
modif
lock
nucleic
acid
lna
methylen
bridg
connect
carbon
seem
abl
reduc
immunostimulatori
effect
sirna
see
duplex
contain
modif
stabil
time
greater
natur
rna
crystal
structur
studi
reveal
adopt
conform
similar
pucker
observ
unmodifi
sugar
nativ
duplex
stretch
well
toler
guid
nonguid
strand
howev
optim
number
placement
necessari
maxim
potenc
optim
sirna
gener
equipot
superior
nativ
sirna
show
increas
thermal
plasma
stabil
furthermor
substanti
improv
sirna
activ
plasma
stabil
achiev
judici
combin
modif
mention
phosphorothio
ps
modif
gener
well
toler
strand
provid
improv
nucleas
resist
linkag
seem
toler
nonguid
guid
strand
sirna
boranophosph
linkag
nonbridg
phosphodiest
oxygen
replac
isoelectron
boran
bh
moieti
boranophosph
sirna
synthes
enzymat
rout
use
rna
polymeras
boranophosph
ribonucleosid
triphosph
transcript
reaction
boranophosph
sirna
activ
nativ
sirna
center
guid
strand
modifi
may
least
ten
time
nucleas
resist
unmodifi
sirna
sirna
duplex
contain
ribonucleosid
rf
synthes
evalu
effect
noncanon
nucleosid
mimet
rna
interfer
thermal
melt
analysi
show
base
pair
rf
adenosin
destabil
rel
uridineadenosin
pair
although
slightli
less
destabil
mismatch
crystal
structur
duplex
contain
rfadenosin
pair
show
local
structur
variat
rel
canon
rna
helix
fluorin
atom
act
hydrogen
bond
acceptor
hydrophob
uridin
wellord
water
structur
seen
around
rf
residu
groov
rapid
amplif
complementari
dna
end
analysi
confirm
cleavag
target
mrna
opposit
rf
placement
site
certain
termin
conjug
report
improv
direct
cellular
uptak
exampl
sirna
conjug
cholesterol
improv
vitro
vivo
cell
permeat
liver
cell
describ
cholesterol
rna
aptam
conjug
show
promis
anim
model
critic
design
concern
select
sirna
duplex
therapeut
use
potenc
specif
two
major
consider
regard
sirna
specif
offtarget
due
silenc
gene
share
partial
homolog
sirna
immun
stimul
due
engag
compon
innat
immun
system
sirna
duplex
combin
bioinformat
method
chemic
modif
strategi
empir
test
requir
address
issu
concomit
first
descript
structur
activ
sirna
set
rule
propos
select
potent
sirna
duplex
sequenc
sever
group
subsequ
develop
sophist
extens
larg
empir
criteria
lead
develop
algorithm
sirna
design
recent
biochem
studi
molecular
mechan
rna
interfer
highlight
key
featur
potent
sirna
duplex
fig
notabl
found
effici
guid
strand
incorpor
risc
complex
perhap
import
factor
determin
sirna
potenc
sirna
duplex
symmetr
question
aros
risc
machineri
abl
determin
strand
use
target
silenc
insight
enigma
came
care
analys
microrna
mirna
endogen
counterpart
sirna
examin
sequenc
larg
number
vertebr
invertebr
mirna
precursor
sequenc
show
predict
thermodynam
stabil
two
end
duplex
unequ
specif
calcul
sever
base
pair
end
duplex
reveal
end
matur
mirna
pair
less
tightli
carrier
strand
end
short
mirna
precursor
show
thermodynam
asymmetri
hypothes
compon
risc
machineri
select
guid
strand
base
asymmetri
experiment
evid
support
asymmetri
hypothesi
deriv
studi
use
chemic
synthes
sirna
transfect
experi
eleg
assay
strand
sirna
target
differ
report
gene
schwarz
et
al
abl
quantifi
rel
effici
risc
incorpor
two
strand
found
risc
machineri
preferenti
incorpor
strand
whose
end
bind
less
tightli
strand
fact
strand
select
could
switch
make
singl
nucleotid
substitut
end
duplex
alter
rel
bind
end
similar
conclus
reach
anoth
group
base
vitro
screen
larg
collect
sirna
vari
potenc
thu
design
sirna
rel
weaker
base
pair
end
desir
guid
strand
may
increas
likelihood
obtain
potent
duplex
issu
offtarget
silenc
subject
intens
studi
number
differ
laboratori
past
sever
year
transcript
profil
studi
confirm
sirna
duplex
potenti
silenc
multipl
gene
addit
intend
target
expect
gene
call
offtarget
signatur
contain
region
complementari
one
two
strand
sirna
duplex
detail
bioinformat
analys
reveal
region
complementar
often
found
utr
offtarget
gene
immedi
suggest
micrornalik
mechan
mirna
gener
interact
utr
region
target
evid
support
concept
came
closer
look
determin
sirna
offtarget
discov
sequenc
complementar
end
guid
strand
mrna
key
offtarget
silenc
critic
nucleo
tide
found
posit
count
end
guid
strand
fig
correspond
socal
seed
region
mirna
shown
determin
mirna
specif
two
strategi
avoid
seed
regionmedi
offtarget
envis
first
simpli
ensur
nucleotid
complementari
posit
guid
strand
uniqu
intend
target
though
theoret
possibl
approach
may
prove
impract
univers
possibl
seedregion
heptam
distinct
sequenc
even
homolog
restrict
utr
may
prove
difficult
identifi
sirna
duplex
satisfi
criteria
potenc
specif
one
altern
recent
publish
work
report
offtarget
substanti
reduc
chemic
modif
nucleotid
within
seed
region
specif
introduct
modif
nucleotid
within
seed
region
shown
inactiv
offtarget
activ
sirna
without
compromis
silenc
intend
mrna
fact
introduct
modif
singl
nucleotid
posit
posit
fig
suffici
suppress
major
offtarget
mechan
anticip
recent
publish
crystal
structur
data
appear
involv
perturb
risc
interact
modifi
nucleotid
interact
outsid
seed
region
also
substanti
affect
sirna
specif
although
seed
region
seem
critic
mrna
recognit
notabl
mrna
cleavag
requir
extens
base
pair
sirna
target
recent
studi
schwarz
et
al
design
sirna
capabl
distinguish
mrna
target
differ
one
nucleotid
show
target
select
depend
locat
mismatch
sirna
mrna
wherea
posit
mismatch
within
seed
region
impart
certain
degre
select
posit
mismatch
guid
strand
especi
posit
fig
produc
highli
discriminatori
sirna
author
hypothes
mismatch
posit
particularli
disrupt
helic
structur
sirnamrna
complex
requir
target
cleavag
second
mechan
wherebi
sirna
duplex
induc
unintend
effect
stimul
innat
immun
system
certain
special
immun
cell
type
demonstr
sirna
duplex
harbor
distinct
sequenc
motif
engag
tolllik
receptor
tlr
plasmacytoid
dendrit
cell
result
increas
product
interferon
immun
stimul
could
pose
signific
problem
therapeut
set
phenomenon
reminisc
result
earlier
studi
dna
antisens
oligonucleotid
distinct
sequenc
socal
cpg
motif
shown
immunostimulatori
subsequ
studi
establish
receptor
unmethyl
cpgcontain
pathogen
dna
innat
immun
regul
engag
antisens
oligonucleotid
case
sirna
seem
mediat
immun
stimul
sever
possibl
strategi
exist
avoid
immun
stimul
sirna
duplex
includ
avoid
offend
sequenc
sirna
design
chemic
modif
inactiv
motif
former
approach
feasibl
present
full
spectrum
stimulatori
motif
identifi
evid
support
latter
approach
come
studi
chemic
modif
posit
nucleotid
within
put
sequenc
elimin
immun
stimul
without
compromis
silenc
activ
anoth
possibl
would
use
sirna
deliveri
strategi
avoid
cell
type
respons
immun
stimul
predict
nucleotid
sequenc
chemic
modif
requir
yield
ideal
sirna
duplex
remain
work
progress
still
recent
advanc
describ
allow
develop
design
algorithm
greatli
increas
likelihood
success
nonetheless
import
note
relev
vitro
measur
potenc
specif
vivo
activ
therapeut
set
yet
establish
exampl
spectrum
offtarget
gene
identifi
tissu
cultur
studi
differ
depend
method
sirna
introduc
cell
also
induct
innat
immun
respons
certain
sirna
sequenc
cell
type
depend
present
prudent
robust
strategi
synthes
screen
substanti
librari
sirna
duplex
target
interest
perhap
even
tile
entir
messeng
rna
identifi
promis
candid
past
sever
year
numer
studi
publish
demonstr
efficaci
silenc
diseas
gene
local
administr
sirna
shrna
anim
model
human
diseas
exogen
endogen
gene
silenc
promis
vivo
result
obtain
across
multipl
organ
tissu
efficaci
demonstr
viral
infect
respiratori
vagin
ocular
diseas
disord
nervou
system
cancer
inflammatori
bowel
diseas
fig
import
aspect
proofofconcept
studi
support
expect
high
specif
rnai
local
rnai
protect
respiratori
vagin
viral
infect
two
report
illustr
efficaci
direct
deliveri
sirna
lung
rodent
monkey
model
rsv
influenza
sever
acut
respiratori
syndrom
sar
infect
without
lipid
formul
mous
model
infect
pulmonari
viral
titer
rsv
parainfluenza
reduc
intranas
deliveri
sirna
formul
transittko
cation
polymerbas
transfect
reagent
target
rsv
parainfluenza
viru
respect
addit
sirna
target
rsv
reduc
pulmonari
patholog
assess
respiratori
rate
leukotrien
induct
inflamm
posit
proofofconcept
studi
mice
led
clinic
trial
rnai
therapeut
target
rsv
anoth
system
multipl
exampl
efficaci
local
deliveri
sirna
eye
proof
concept
success
achiev
anim
model
ocular
neovascular
scar
use
salin
lipid
formul
intravitr
inject
sirna
target
vascular
endotheli
growth
factor
vegf
formul
phosphatebuff
salin
effect
reduc
area
ocular
neovascular
onethird
twothird
two
mous
model
addit
sirna
target
vegf
transform
growth
receptor
type
ii
formul
transittko
inject
directli
mous
eye
result
inhibit
laser
photocoagulationinduc
choroid
neovascular
latex
beadinduc
collagen
deposit
inflammatori
cell
infiltr
respect
lung
multipl
sirna
formul
effect
eye
encourag
proofofconcept
studi
anim
model
led
clinic
trial
sirna
target
vegf
pathway
amd
nervou
system
rnai
particularli
use
valid
diseas
target
vivo
sever
formul
includ
salin
polym
complex
lipid
liposom
formul
efficaci
deliv
sirna
local
nervou
system
numer
diseas
model
simplest
mode
deliveri
intracerebroventricular
intrathec
intraparenchym
infus
nake
sirna
formul
buffer
isoton
salin
result
silenc
specif
neuron
molecular
mrna
target
multipl
region
central
peripher
nervou
system
nake
sirna
formul
buffer
isoton
salin
dose
mg
per
day
typic
requir
effect
target
gene
silenc
polym
complex
lipid
liposom
formul
polyethylen
imin
pei
ifect
dotap
jetsidop
facilit
cellular
uptak
reduc
dose
sirna
requir
effect
neuron
target
silenc
vivo
approxim
local
viral
deliveri
shrna
nervou
system
report
vivo
adenovir
adenoassoci
viral
aav
lentivir
deliveri
normal
mice
well
anim
model
spinocerebellar
ataxia
huntington
diseas
amyotroph
later
sclerosi
al
alzheim
diseas
abnorm
diseas
phenotyp
includ
behavior
neuropatholog
normal
notabl
vivo
studi
date
target
gene
express
neuron
remain
seen
whether
silenc
vivo
achiev
nervoussystem
cell
type
oligodendrocyt
astrocyt
moreov
endogen
neuron
target
express
target
gene
typic
reduc
partial
case
littl
yet
modest
reduct
mrna
result
mark
effect
specif
behavior
appropri
target
gene
applic
oncolog
direct
deliveri
sirna
viral
deliveri
shrna
tumor
success
inhibit
xenograft
growth
sever
mous
model
number
approachesinclud
lipidbas
formul
transmesseng
complex
pei
cholesterololigoarginin
protaminefab
fusion
protein
atelocollagen
shown
facilit
deliveri
tumor
cell
notabl
sirna
deliveri
approach
effect
sever
even
singl
intratumor
inject
sirna
microgram
dose
recent
aptamersirna
chimer
rna
also
use
success
facilit
sirna
deliveri
vivo
result
tumor
regress
xenograft
model
prostat
cancer
viral
vectorbas
deliveri
shrna
directli
tumor
site
also
use
effect
mous
model
adenocarcinoma
ewe
sarcoma
prostat
cancer
multipl
deliveri
strategi
effect
mous
tumor
model
aptam
approach
potenti
substanti
simplifi
deliveri
aptam
avail
tumorspecif
receptor
prostatespecif
membran
antigen
pmsa
largescal
synthesi
construct
feasibl
inflammatori
bowel
diseas
direct
deliveri
sirna
target
tumor
necrosi
lipofectamin
formul
recent
shown
reduc
abund
also
colon
inflamm
administr
enema
report
togeth
studi
sirna
target
herp
simplex
ref
suggest
mucos
surfac
access
liposom
sirna
formul
past
sever
year
number
studi
publish
demonstr
silenc
diseas
gene
system
administr
sirna
fig
review
ref
studi
silenc
endogen
express
gene
shown
promis
vivo
result
differ
diseas
context
exampl
efficaci
demonstr
mous
model
hypercholesterolemia
rheumatoid
arthriti
work
system
rnai
target
exogen
gene
shown
promis
model
viral
infect
hepat
b
viru
hbv
influenza
viru
ebola
viru
tumor
xenograft
critic
success
studi
use
chemic
modif
deliveri
formul
impart
desir
pharmacokinet
properti
sirna
duplex
also
promot
cellular
uptak
tissu
organ
rnai
proof
concept
demonstr
direct
rnai
repres
local
deliveri
rnai
carri
success
specif
tissu
organ
includ
lung
eye
nervou
system
tumor
digest
system
vagina
system
rnai
repres
intraven
deliveri
rnai
carri
success
lung
tumor
liver
joint
specif
diseas
model
indic
efficaci
achiev
soutschek
et
al
demonstr
effect
silenc
apolipoprotein
apob
mice
intraven
administr
cholesterolconjug
sirna
duplex
three
daili
inject
cholesterolconjug
sirna
dose
mg
kg
result
silenc
apob
mrna
respect
liver
jejunum
two
princip
site
apob
express
mechan
action
proven
rnai
mediat
mrna
silenc
produc
reduct
apob
protein
abund
plasma
reduct
total
cholesterol
therapeut
relev
find
complet
consist
known
function
apob
lipid
metabol
cholesterol
conjug
impart
critic
pharmacokinet
cellular
uptak
properti
sirna
duplex
advanc
system
rnai
optim
deliveri
recent
report
recent
zimmermann
et
al
made
use
sirna
duplex
formul
stabl
nucleic
acid
lipid
particl
snalp
recapitul
silenc
apob
mice
rodent
studi
silenc
produc
singl
dose
snalpformul
sirna
mg
kg
greater
report
earlier
studi
use
cholesterolconjug
sirna
importantli
therapeut
silenc
apob
also
demonstr
nonhuman
primat
singl
dose
mg
kg
sirna
encapsul
snalp
formul
reduc
apob
mrna
liver
cynomolgu
monkey
mous
experi
apob
silenc
accompani
substanti
reduct
serum
cholesterol
lowdens
lipoprotein
furthermor
silenc
shown
last
least
singl
dose
addit
treatment
seem
well
toler
transient
increas
liver
enzym
report
evid
toxic
primat
studi
repres
import
step
forward
develop
system
rnai
therapeut
applic
moreov
gener
applic
snalp
formul
hepat
deliveri
sirna
demonstr
anim
model
hbv
ebola
viru
infect
mous
tumor
xenograft
model
efficaci
system
rnai
demonstr
use
varieti
deliveri
strategi
review
ref
system
deliv
cation
cardiolipin
liposom
contain
sirna
specif
inhibit
tumor
growth
xenograft
model
human
prostat
cancer
vascular
endotheli
growth
factor
target
sirna
complex
selfassembl
nanoparticl
consist
polyethylen
glycolconjug
pegyl
pei
argglyasp
peptid
attach
distal
end
peg
accumul
tumor
caus
inhibit
express
intraven
administr
complex
tumorbear
mice
inhibit
tumor
angiogenesi
growth
rate
simpler
pei
formul
also
shown
efficaci
xenograft
tumor
model
complex
sirna
duplex
atelocollagen
system
administr
atelocollagensirna
complex
mark
effect
subcutan
tumor
xenograft
well
bone
metastas
anoth
recent
describ
deliveri
strategi
made
use
recombin
antibodi
fusion
protein
achiev
cell
typespecif
deliveri
describ
song
et
al
fuse
nucleic
acid
bind
protein
protamin
c
terminu
fragment
antibodi
fab
target
envelop
protein
system
administr
fabprotamin
fusion
abl
deliv
sirna
mixtur
mous
melanoma
cell
engin
express
envelop
protein
lead
substanti
inhibit
tumor
growth
mice
tumor
deriv
cell
express
envelop
protein
unaffect
anoth
exampl
liganddirect
deliveri
hulieskovan
et
al
made
use
transferrinconjug
nanoparticl
deliv
sirna
target
oncogen
ewsfli
translocationderiv
mrna
mous
model
metastat
ewe
sarcoma
remov
target
ligand
use
control
sirna
sequenc
elimin
antitumor
effect
effect
deliveri
perhap
challeng
remain
consider
success
translat
rnai
clinic
broad
use
patient
anim
studi
review
nonvir
viral
approach
local
system
administr
multipl
formul
salin
lipid
complex
conjug
small
molecul
polym
protein
antibodi
use
achiev
efficaci
howev
approach
distinct
advantag
disadvantag
clinic
translat
requir
care
consider
although
viral
deliveri
provid
potenti
advantag
singl
administr
could
lead
durabl
downmodul
target
patholog
protein
major
risk
highlight
recent
aav
deliveri
shrna
excess
divers
endogen
rnai
mechan
occur
result
pronounc
toxic
mice
clearli
drug
critic
abl
control
level
drug
durat
drug
action
exposur
safe
still
efficaci
distinct
contrast
nonvir
deliveri
sirna
substanti
liabil
viral
deliveri
imposs
fulli
predict
drug
exposur
regard
amount
time
addit
shrna
enter
rnai
pathway
upstream
therapeut
applic
sirna
viral
vector
express
high
level
shrna
may
interfer
endogen
mirna
biogenesi
princip
consider
select
local
versu
system
sirna
administr
dose
need
achiev
suffici
drug
concentr
target
tissu
possibl
effect
exposur
nontarget
tissu
drug
one
extrem
certain
tissu
efficaci
far
demonstr
local
deliveri
current
formul
may
provid
suffici
drug
concentr
target
tissu
system
deliveri
howev
tissu
exampl
liver
intraven
dose
low
mg
kg
rang
liposom
formul
provid
robust
therapeut
gene
silenc
gener
pharmacolog
approach
dose
sirna
requir
efficaci
substanti
lower
sirna
inject
near
target
tissu
administ
system
given
high
specif
sirna
intend
molecular
target
exposur
nontarget
tissu
drug
issu
molecular
target
express
nontarget
tissu
import
role
normal
cellular
function
within
tissu
case
local
deliveri
focus
exposur
might
circumv
undesir
side
effect
result
system
deliveri
liposom
lipid
complex
conjug
small
molecul
polym
protein
antibodi
use
facilit
deliveri
sirna
target
cell
deliveri
partner
robust
efficaci
achiev
dose
sirna
substanti
lower
less
frequent
addit
nonsirna
compon
howev
associ
biolog
largescal
manufactur
consider
lipid
polym
cytotox
effect
might
limit
use
sirna
deliveri
particular
diseas
indic
dose
paradigm
howev
seem
possibl
identifi
lipidbas
formul
dose
regimen
cytotox
minim
risk
histopatholog
reduc
small
molecul
protein
antibodi
use
conjug
also
need
consid
standpoint
biolog
activ
endogen
molecul
exampl
receptor
interact
import
role
normal
physiolog
use
endogen
molecul
potenti
deliveri
may
alter
normal
function
produc
undesir
side
effect
case
addit
nonsirna
molecul
molecul
increas
complex
manufactur
particularli
larg
scale
scientif
technic
advanc
approach
may
provid
mark
enhanc
sirna
deliveri
accept
biolog
manufactur
consider
first
clinic
trial
rnai
therapeut
target
vegf
pathway
wet
form
amd
rsv
genom
treatment
rsv
infect
case
initi
approach
direct
administr
rnai
therapeut
salin
formul
case
highli
valid
diseas
target
inhibit
sirna
furthermor
direct
administr
sirna
eye
lung
amd
rsv
infect
respect
maxim
chanc
deliv
suffici
therapeut
relev
concentr
drug
tissu
interest
phase
trial
patient
seriou
progress
amd
sirna
target
vegf
report
provid
doserel
benefit
respect
sever
endpoint
includ
near
vision
lesion
size
http
also
test
efficaci
diabet
macular
edema
phase
trial
began
earli
http
wwwacuitypharma
sirna
target
vegf
recent
complet
phase
trial
patient
wet
form
amd
report
well
toler
addit
report
stabil
improv
visual
acuiti
subset
patient
http
wwwsirnacomwtpageocular
rsv
infect
two
phase
trial
sirna
complet
healthi
adult
volunt
one
largest
human
studi
rnai
therapeut
found
safe
well
toler
http
phxcorporateirnetphoenixzhtml
highlight
addit
rnai
therapeut
candid
expect
advanc
clinic
within
come
year
includ
sirna
target
pandem
influenza
http
wwwalnylam
comtherapeuticprogramsprogramsasp
hepat
c
http
wwwsirnacomwtpageantivir
trial
advanc
clinic
near
futur
excit
potenti
sirna
may
demonstr
therapeut
approach
rnai
provid
solut
major
drawback
tradit
pharmaceut
drug
tabl
princip
advantag
rnai
smallmolecul
protein
therapeut
target
includ
nondrugg
target
inhibit
rnai
lead
compound
rapidli
identifi
optim
primari
challeng
associ
smallmolecul
drug
identif
highli
select
potent
compoundsa
difficult
timeconsum
process
target
unsuccess
rnai
identif
highli
select
potent
sequenc
rapid
demonstr
numer
molecular
target
across
molecular
class
protein
antibodi
drug
main
technic
challeng
product
protein
accept
cellular
product
level
often
difficult
achiev
biolog
therapeut
class
aggreg
continu
major
issu
contrast
sirna
synthet
easi
produc
chemistri
standpoint
cours
rnai
definit
antagon
specif
molecular
target
possibl
wherea
small
molecul
protein
antibodi
provid
opportun
agon
molecular
target
overal
howev
rnai
hold
great
promis
therapeut
approach
provid
major
new
class
drug
fill
signific
gap
modern
medicin
signific
progress
made
advanc
rnai
therapeut
remark
short
period
time
start
discoveri
rnai
mediat
long
doublestrand
rna
caenorhabd
elegan
fire
mello
public
tuschl
max
planck
institut
colleagu
synthet
sirna
silenc
target
gene
mammalian
system
rel
short
year
sinc
seen
explos
report
therapeut
applic
har
rnai
clearli
princip
challeng
remain
achiev
broadest
applic
rnai
therapeut
hurdl
deliveri
said
tremend
progress
made
new
conjug
complex
lipidbas
approach
although
challeng
sirna
deliveri
yet
solv
cell
type
organ
challeng
met
develop
rnai
therapeut
limit
primarili
target
valid
possibl
rapidli
advanc
rnai
therapeut
potenti
diseas
target
clinic
studi
therebi
treat
diseas
new
manner
near
futur
ongo
clinic
trial
sirna
macular
degener
rsv
may
reveal
excit
potenti
rnai
therapeut
next
major
class
drug
molecul
